CDK4/6 Inhibitoren: Wo stehen wir heute? EBCC11 Keynote Lecture - Therapieansprechen - Oncoletter, Webportal für Onkologie und onkologische Hämatologie mit integrierten Links zu Wikipedia und Pharma Wiki sowie NCI, Kompendium, Medline und wichtigen Kongressen wie ASCO, ASH, SABCS, ESMO, EHA, Darmkrebs, Nierenkrebs, Brustkrebs, Prostatakrebs

Startseite

Kongressberichte & Archiv

Archiv 2018

11th European Breast Cancer Conference (EBCC-11)

Interviews

Prof. Dr. med. Nadia Harbeck, München

Prof. Dr. med. Nadia Harbeck, München

Interview geführt von Renate Haidinger, Brustkrebs Deutschland e.V. zu folgenden Themen:

CDK4/6 Inhibitoren: Wo stehen wir heute?
EBCC11 Keynote Lecture - Therapieansprechen

News

LONSURF® (Trifluridin/Tipiracil)

08-09-2020 15:44

Lonsurf ist jetzt auch indiziert zur Behandlung von erwachsenen Patienten mit metastasiertem Magenkarzinom einschliesslich Adenokarzinom des gastroösophagealen Übergangs, die bereits mit mindestens zwei Chemotherapien behandelt wurden. Zu diesen Therapien zählen Fluoropyrimidin-, Platin- und Taxan- oder Irinotecan-basierte Chemotherapien und gegebenfalls einer gezielten HER2/neu-Therapie. (Quelle Compendium.ch)

Rigosertib Fails to Meet OS End Point in Higher-Risk MDS

31-08-2020 09:51

More info

LIBRETTO-001 Trial Shows Promise for Selpercatinib in NSCLC Marked by RET Gene Fusions

31-08-2020 09:49

More info

Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study

31-08-2020 09:45

More info

CAR T for R/R multiple myeloma with idecabtagene vicleucel (ide-cel) resubmitted to FDA.

03-08-2020 13:16

MORE INFO

Atezolizumab approved by FDA in combination with cobimetinib & vemurafenib in BRAF V600+ melanoma.

03-08-2020 13:09

MORE INFO

Tafasitamab-cxicx approved in combination with lenalidomide in adult R/R diffuse large B-cell lymphoma (DLBCL).

03-08-2020 12:54

MORE INFO

Osimertinib, an irreversible EGFR-TKI, granted breakthrough therapy designation by FDA as an adjuvant treatment for Sage Ib/II/IIIA EGFR-mutated NSCLC after complete tumor resection.

03-08-2020 12:51

MORE INFO

Prof. Dr. med. Nadia Harbeck, München

News

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

LONSURF® (Trifluridin/Tipiracil)

Rigosertib Fails to Meet OS End Point in Higher-Risk MDS

LIBRETTO-001 Trial Shows Promise for Selpercatinib in NSCLC Marked by RET Gene Fusions

Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study

CAR T for R/R multiple myeloma with idecabtagene vicleucel (ide-cel) resubmitted to FDA.

Atezolizumab approved by FDA in combination with cobimetinib & vemurafenib in BRAF V600+ melanoma.

Tafasitamab-cxicx approved in combination with lenalidomide in adult R/R diffuse large B-cell lymphoma (DLBCL).

Osimertinib, an irreversible EGFR-TKI, granted breakthrough therapy designation by FDA as an adjuvant treatment for Sage Ib/II/IIIA EGFR-mutated NSCLC after complete tumor resection.

Newsletter